Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

LakeShore Biopharma Co., Ltd. (LSB) had Revenue of $85.67M for the most recently reported fiscal year, ending 2025-03-31.

Quarterly Annual

Figures for fiscal year ending 2025-03-31

Income Statement Financials
Revenue	$85.67M
Net Income	$-13.93M
Cost of Goods Sold	$15.01M
Gross Profit	$70.66M
Operating Expenses	$97.69M
Operating Income	$-12.02M
Non-Operating Income/Expense	$-2.04M
Pre-Tax Income	$-14.06M
Normalized Pre-Tax Income	$-14.06M
Income after Taxes	$-13.93M
Income from Continuous Operations	$-13.93M
Consolidated Net Income/Loss	$-13.93M
Normalized Income after Taxes	$-13.93M
EBIT	$-12.02M
EBITDA	$-6.92M
Weighted-Average Shares Outstanding (Basic)	19.16M
Weighted-Average Shares Outstanding (Diluted)	19.16M
Earnings per Share (EPS) (Basic)	$-0.73
Earnings per Share (EPS) (Diluted)	$-0.73
Balance Sheet Financials
Current Assets	$117.33M
Property, Plant, and Equipment	$57.61M
Long-Term Assets	$73.20M
Total Assets	$190.53M
Current Liabilities	$114.90M
Long-Term Debt	$3.27M
Long-Term Liabilities	$6.01M
Total Liabilities	$120.91M
Common Equity	$69.62M
Tangible Shareholders Equity	$59.47M
Shareholders Equity	$69.62M
Common Shares Outstanding	20.77M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-16.85M
Cash Flow from Investing Activities	$-2.37M
Cash Flow from Financial Activities	$-0.50M
Beginning Cash	$34.35M
End Cash	$14.97M
Increase/Decrease in Cash	$-19.37M
Stock-Based Compensation	$1.89M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.02
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.04
Debt to Equity Ratio	0.83
Gross Margin	82.47%
Operating Margin	-14.03%
EBIT Margin	-14.03%
EBITDA Margin	-8.07%
Pre-Tax Profit Margin	-16.41%
Profit Margin	-16.26%
Free Cash Flow	$-18.51M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.45
Inventory Turnover	0.47
Receiveable Turnover	1.23
Days Sales in Receivables	297.31
Return on Equity	-20.01%
Return on Tangible Equity	-23.42%
Return on Assets	-7.31%
Return on Investments	-19.11%
Book Value Per Share	$3.35
Free Cash Flow per Share	$-0.97
Operating Cash Flow per Share	$-0.88

Data from Zacks Investment Research, Inc.